Arizona 2023 Regular Session

Arizona House Bill HB2723 Latest Draft

Bill / Introduced Version Filed 02/06/2023

                            REFERENCE TITLE: sickle cell disease; annual review             State of Arizona House of Representatives Fifty-sixth Legislature First Regular Session 2023           HB 2723           Introduced by  Representatives Marshall: Diaz, Gillette, Hendrix, Smith                    An Act   amending title 36, chapter 29, article 1, Arizona Revised Statutes, by adding section 36-2903.14; relating to the Arizona health care cost containment system.     (TEXT OF BILL BEGINS ON NEXT PAGE)   

 

 

 

REFERENCE TITLE: sickle cell disease; annual review
State of Arizona House of Representatives Fifty-sixth Legislature First Regular Session 2023
HB 2723
Introduced by  Representatives Marshall: Diaz, Gillette, Hendrix, Smith

REFERENCE TITLE: sickle cell disease; annual review

 

 

 

 

State of Arizona

House of Representatives

Fifty-sixth Legislature

First Regular Session

2023

 

 

 

HB 2723

 

Introduced by 

Representatives Marshall: Diaz, Gillette, Hendrix, Smith

 

 

 

 

 

 

 

 

An Act

 

amending title 36, chapter 29, article 1, Arizona Revised Statutes, by adding section 36-2903.14; relating to the Arizona health care cost containment system.

 

 

(TEXT OF BILL BEGINS ON NEXT PAGE)

 

 Be it enacted by the Legislature of the State of Arizona: Section 1. Title 36, chapter 29, article 1, Arizona Revised Statutes, is amended by adding section 36-2903.14, to read: START_STATUTE36-2903.14. Sickle cell disease; annual review of medications, treatments and services; annual report A. The administration shall conduct an annual review of all medications and forms of treatment for sickle cell disease and services available to members with a diagnosis of sickle cell disease that are eligible for coverage under this article. The purpose of the annual review is to determine whether the available covered medications, treatments and services are adequate to meet the needs of members with a diagnosis of sickle cell disease and whether the administration should seek to add additional medications, treatments or services. B. When conducting the annual review required by this section, the administration shall solicit and consider input from the general public, with specific emphasis on attempting to receive input from persons or groups with knowledge and experience in the area of sickle cell disease treatment. C. On or before January 15, 2024, and on or before January 15 each year thereafter, the administration shall submit a report to the governor, the speaker of the house of representatives, the president of the senate and the health and human services committees of the house of representative and senate, or their successor committees, and shall provide a copy of the report to the secretary of state. The report shall detail the administration's findings from the annual review required by this section, as well as any recommendations based on those findings. The administration shall post the annual report required by this section on its public website. END_STATUTE 

Be it enacted by the Legislature of the State of Arizona:

Section 1. Title 36, chapter 29, article 1, Arizona Revised Statutes, is amended by adding section 36-2903.14, to read:

START_STATUTE36-2903.14. Sickle cell disease; annual review of medications, treatments and services; annual report

A. The administration shall conduct an annual review of all medications and forms of treatment for sickle cell disease and services available to members with a diagnosis of sickle cell disease that are eligible for coverage under this article. The purpose of the annual review is to determine whether the available covered medications, treatments and services are adequate to meet the needs of members with a diagnosis of sickle cell disease and whether the administration should seek to add additional medications, treatments or services.

B. When conducting the annual review required by this section, the administration shall solicit and consider input from the general public, with specific emphasis on attempting to receive input from persons or groups with knowledge and experience in the area of sickle cell disease treatment.

C. On or before January 15, 2024, and on or before January 15 each year thereafter, the administration shall submit a report to the governor, the speaker of the house of representatives, the president of the senate and the health and human services committees of the house of representative and senate, or their successor committees, and shall provide a copy of the report to the secretary of state. The report shall detail the administration's findings from the annual review required by this section, as well as any recommendations based on those findings. The administration shall post the annual report required by this section on its public website. END_STATUTE